Physician profile
Strutha C Rouse
NPI 1508819301
$4,998.67
in general payments reported to CMS, 2019-2025
24 companies · $991 in 2025
The $991 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $174 · 2021: $394 · 2022: $1,503 · 2023: $816 · 2024: $511 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $972.35 | 2019-2025 | Foresee Home |
| US Retina LLC | $813.55 | 2019-2022 | |
| Astellas Pharma US INC | $508.73 | 2023-2025 | Izervay |
| Genentech USA, INC. | $480.51 | 2019-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $433.76 | 2023-2025 | Syfovre |
| Allergan, INC. | $307.36 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $284.45 | 2024-2025 | Xdemvy |
| Abbvie INC. | $231.41 | 2022-2025 | Ozurdex |
| Regeneron Healthcare Solutions, INC. | $226.65 | 2019-2025 | Eylea Hd, Eylea |
| Amgen INC. | $115.66 | 2024-2025 | Tepezza |
| Spark Therapeutics, INC. | $97.08 | 2019 | |
| Alcon Vision LLC | $92.72 | 2019-2025 | Unity |
| Harrow Eye, LLC | $66.32 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $64.16 | 2019-2021 | |
| Genentech, INC. | $57.24 | 2025 | Vabysmo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $47.20 | 2019-2022 | |
| Horizon Therapeutics Plc | $43.27 | 2023 | Tepezza |
| Bausch & Lomb Americas INC. | $40.88 | 2022-2024 | Xipere, Visudyne |
| Glaukos Corporation | $25.77 | 2025 | Idosetr |
| Rxsight INC | $21.34 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Mallinckrodt Hospital Products INC. | $20.72 | 2025 | Acthar |
| Rayner Intraocular Lenses Limited | $18.80 | 2025 | Omidria |
| Aerie Pharmaceuticals, INC. | $17.40 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,869.91 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Strutha Rouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.